CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 19 enrolled
Drug / intervention
Pandel Cream 0.1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01137032
NCT01137032Phase 4Completed
CompareCT.gov

An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population

Fougera Pharmaceuticals Inc.·interventional·Posted Jun 4, 2010·Updated May 4, 2016

In Brief

A Phase 4 clinical trial evaluating Pandel Cream 0.1% for Psoriasis and Atopic Dermatitis. Completed, enrolled 19 participants across 3 sites.

Detailed Summary

The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic dermatitis involving greater than 20% body surface area.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Atopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 4, 2010
Enrollment StartJun 1, 2004
Primary CompletionAug 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.1 years ago

Interventions

Pandel Cream 0.1%drug

A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days